MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...
Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered
Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...
YolTech’s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment
China-based YolTech Therapeutics announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products...
Cedicine Biotech’s Umbilical Cord Blood Mononuclear Cell Injection Gains CDE Approval for Clinical Trial
China-based Cedicine Biotechnology announced today that the Center for Drug Evaluation (CDE) of the National...
Alphamab Oncology’s JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer
China-based Alphamab Oncology (HKG: 9966) announced today that its drug candidate JSKN003 has received Orphan...
Pierre Fabre’s Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer
France-based Pierre Fabre Laboratories announced that Braftovi (encorafenib) in combination with cetuximab has been approved...
Henlius Biotech’s HLX14 Recommended for EU Approval by EMA’s CHMP
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) announced on July 28, 2025, that the European...
Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer’s Treatment
China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered...
Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...
Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific
China-based Tigermed (SHE: 300347, HKG: 3347) announced on July 29, 2025, that it has completed...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Type 2 Diabetes Treatment with Insulin
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced that the National Medical Products Administration...
Antengene’s XPOVIO Approved for New Multiple Myeloma Indication by China’s NMPA
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that the China National Medical Products Administration...
Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement
The Shanghai Biomedicine Merger and Acquisition Fund under SIIC Capital has entered into a share...
AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies
UK-based AstraZeneca’s (AZ, NASDAQ: AZN) Biopharmaceuticals Business Unit (BBU), established last year, is undergoing a...
Wuxi Apptec Reports Strong Q2 2025 Results with 20.6% Revenue Growth
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) announced strong growth in...
BMS and Bain Capital Launch New Autoimmune Disease Focused Biopharma Company
US major Bristol-Myers Squibb (BMS; NYSE: BMY) and Bain Capital announced the formation of a...
BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its PD-1 antibody...
Bristol-Myers Squibb Gains NMPA Approval for Opdivo-Yervoy Combo in NSCLC
US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that it has received another indication approval...
NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs
On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...
Tibet Aim Pharm’s Major Shareholder Transfers Stake to Beijing Fuhao
China-based Tibet Aim Pharm, Inc. (SHE: 002826) announced that its controlling shareholder and actual controller,...